PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation

    Caballero-Velázquez T (1), Calderón-Cabrera C (1), López-Corral L (2), Puig N (2), Marquez-Malaver F (1), Pérez-López E (2), García-Calderón C (1), Rosso-Fernández CM (1), Caballero Barrigón D (2), Martín J (1), Mateos MV (2), San Miguel J (3), Pérez-Simón JA (4); European Myeloma Network.

    (1) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.
    (2) Department of Hematology, Complejo Asistencial Universitario de Salamanca-IBSAL-CIBERONC, Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.
    (3) Clínica Universidad de Navarra, Centro Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (4) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.

    Bone Marrow Transplantation 24 de SETEMBRO de 2019

  • Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma

    Rosiñol L (1), Oriol A (2), Rios R (3), Sureda A (4), Blanchard MJ (5), Hernández MT (6), Martínez-Martínez R (7), Moraleda JM (8), Jarque I (9), Bargay J (10), Gironella M (11), de Arriba F (12), Palomera L (13), Gonzalez-Montes Y (14), Marti J (15), Krsnik I (16), Arguiñano JM (17), Gonzalez ME (18), Gonzalez AP (19), Casado LF (20), Lopez-Anglada L (21), Paiva B (22), Mateos MV (23), San Miguel J (24), Lahuerta JJ (25), Bladé J (26).

    (1) Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Spain
    (2) Clinical Hematology, ICO - Hosp Germans Trias i Pujol, Spain.
    (3) Hospital Universitario Virgen de las Nieves, Spain.
    (4) Haematology, Institut Català d'Oncologia, Spain.
    (5) Hematology, Hospital Ramon y Cajal, Spain.
    (6) Hematology, Hospital Universitario de Canaria, Spain.
    (7) Hospital Clínico San Carlos.
    (8) Hematology., Hospital Universitario Virgen de la Arrixaca. University of Murcia, Spain.
    (9) Hematology, Hospital Universitari i Politècnic La Fe, Spain.
    (10) Hospital Universitario Son Llàtzer, Spain.
    (11) Hospital Universitario Vall d'Hebron, Spain.
    (12) Hematologia y Oncología Médica, Hospital General Universitario Morales Meseguer, Spain.
    (13) Hematology, Hospital Clínico, Spain.
    (14) hematologia ICO, hospital josep trueta, Spain.
    (15) Hospital la Mutua de Terrassa, Spain.
    (16) Hematology, Hospital Universitario Puerta de Hierro, Spain.
    (17) Complejo Hospitalario de Navarra, Spain.
    (18) Hematology, Hospital Cabueñes, Spain.
    (19) Hospital Universitario Central de Asturias, Spain.
    (20) Hematology, Hospital Virgen de la Salud, Spain.
    (21) Hospital Universitario, Spain.
    (22) Hematology, Clinica Universidad de Navarra, Spain.
    (23) Department of Hematology, University Hospital of Salamanca/IBSAL/Cancer Research Center, Spain.
    (24) Clinica Universidad de Navarra, Universidad de Navarra, Spain.
    (25) Hematology, Hospital Universitario 12 de Octubre, Spain.
    (26) Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain.

    Blood 04 de SETEMBRO de 2019

  • A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    San-Miguel JF (1), Echeveste Gutierrez MA (2), Špicka I (3), Mateos MV (4), Song K (5), Craig MD (6), Bladé J (7), Hájek R (8), Chen C (9), Di Bacco A (10), Estevam J (10), Gupta N (10), Byrne C (10), Lu V (10), van de Velde H (10), Lonial S (11).

    (1) Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA), El Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
    (2) Hospital Universitario Donostia, San Sebastián, Spain.
    (3) 1Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
    (4) Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain.
    5 Division of Hematology, University of British Columbia, Vancouver, BC, Canada.
    (6) Department of Medicine, West Virginia University, Morgantown, WV, USA.
    (7) Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain.
    (8) Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Czech Republic.
    (9) Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON, Canada.
    (10) Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
    (11) Winship Cancer Institute of Emory University, Atlanta, GA, USA.

    Haematologica 01 de SETEMBRO de 2019

  • Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma

    Usmani SZ (1), Schjesvold F (2), Oriol A (3), Karlin L (4), Cavo M (5), Rifkin RM (6), Yimer HA (7), LeBlanc R (8), Takezako N (9), McCroskey RD (10), Lim ABM (11), Suzuki K (12), Kosugi H (13), Grigoriadis G (14), Avivi I (15), Facon T (16), Jagannath S (17), Lonial S (18), Ghori RU (19), Farooqui MZH (19), Marinello P (19), San-Miguel J (20); KEYNOTE-185 Investigators.

    (1) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (2) Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    (3) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
    (4) Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
    (5) Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
    (6) Rocky Mountain Cancer Centers, Denver, CO, USA.
    (7) Texas Oncology, Tyler, TX, USA.
    (8) Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est de L'Ile de Montréal, University of Montreal, Montreal, QC, Canada.
    (9) Disaster Medical Center, Tokyo, Japan.
    (10) Northwest Medical Specialties, PLLC, Puyallup, WA, USA.
    (11) Austin Health, Austin Hospital, Heidelberg, VIC, Australia.
    (12) Japanese Red Cross Medical Center, Tokyo, Japan.
    (13) Ogaki Municipal Hospital, Ogaki, Japan.
    (14) Monash Health, Melbourne, VIC, Australia.
    (15) Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
    (16) Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.
    (17) Mount Sinai Hospital, New York, NY, USA.
    (18) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (19) Merck & Co, Inc, Kenilworth, NJ, USA.
    (20) Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    The Lancet. Haematology 18 de JULHO de 2019

  • Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma

    Mateos MV (1), Blacklock H (2), Schjesvold F (3), Oriol A (4), Simpson D (5), George A (6), Goldschmidt H (7), Larocca A (8), Chanan-Khan A (9), Sherbenou D (10), Avivi I (11), Benyamini N (12), Iida S (13), Matsumoto M (14), Suzuki K (15), Ribrag V (16), Usmani SZ (17), Jagannath S (18), Ocio EM (19), Rodriguez-Otero P (20), San Miguel J (20), Kher U (21), Farooqui M (21), Liao J (21), Marinello P (21), Lonial S (22); KEYNOTE-183 Investigators.

    (1) Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain.
    (2) Middlemore Hospital, Auckland, New Zealand.
    (3) Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    (4) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Triasi Pujol, Barcelona, Spain.
    (5) North Shore Hospital, Auckland, New Zealand.
    (6) Wellington Blood and Cancer Center, Wellington, New Zealand.
    (7) University Hospital Heidelberg and National Center of Tumor Diseases in Heidelberg, Heidelberg, Germany.
    (8) Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
    (9) Mayo Clinic, Jacksonville, FL, USA.
    (10) University of Colorado Cancer Center, Denver, CO, USA.
    (11) Sourasky Medical Center, Haifa, Israel.
    (12) Rambam Health Care Campus, HaAliya HaShniya, Israel.
    (13) Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
    (14) National Hospital Organization, Shibukawa Medical Center, Shibukawa, Gunma, Japan.
    (15) Japanese Red Cross, Tokyo, Japan.
    (16) Institut Gustave Roussy, Villejuif, France.
    (17) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (18) The Mount Sinai Medical Hospital, New York, NY, USA.
    (19) Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
    (20) Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (21) Merck & Co, Kenilworth, NJ, USA.
    (22) Winship Cancer Institute, Emory University, Atlanta, GA, USA.

    The Lancet. Haematology 18 de JULHO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra